BioCentury | Apr 15, 2013
Company News

Martek, Nutraceutical Corp. sales and marketing update

...Neuromins docosahexaenoic acid (DHA) in retail outlets in the U.S. under Nutraceutical's Solaray brand name. Martek Biosciences Corp....
BioCentury | Apr 15, 2013
Company News

Martek management update

Martek Biosciences Corp. (MATK), Columbia, Md. Business: Foods, Drug discovery Hired: Jerome Keller as SVP of sales and marketing, formerly VP of sales at Merck & Co. WIR Staff...
BioCentury | Apr 15, 2013
Company News

Martek sales and marketing update

...acid (DHA) and arachidonic acid (ARA), believed to be associated with mental and visual development. Martek Biosciences Corp....
BioCentury | Apr 15, 2013
Company News

Martek other research news

...milk, and schizophrenia in adults. The company markets Neuromins DHA, a single-nutrient source of DHA. Martek Biosciences Corp....
BioCentury | Apr 15, 2013
Company News

Martek sales and marketing update

...acids docosahexanoic acid (DHA) and arachadonic acid (ARA) that are found in human breast milk. Martek Biosciences Corp....
BioCentury | Apr 15, 2013
Clinical News

Martek regulatory update

...with ARA levels comparable to those found in human breast milk without introducing excess EPA. Martek Biosciences Corp....
BioCentury | Jan 30, 2012
Finance

Small stakes

...2010 for a profit of $2,591. In June 2009, he purchased $5,208 of nutraceuticals play Martek Biosciences Corp....
...which he sold that December for a $2,004 profit. Royal DSM N.V. (Euronext:DSM) acquired Martek...
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

...billion. The four companies were Crucell N.V. , Cypress Bioscience Inc. , Eurand N.V. and Martek Biosciences Corp....
BioCentury | Mar 7, 2011
Company News

Martek, Royal DSM deal

...DSM completed its previously announced offer for Martek (see BioCentury, Jan. 3 & Jan. 24). Martek Biosciences Corp....
BioCentury | Jan 24, 2011
Company News

Martek, Royal DSM deal

...Royal DSM began its cash tender offer to acquire nutraceuticals company Martek for $31.50 per share...
...per share, or about $1.1 billion. The offer expires Feb. 18 (see BioCentury, Jan. 3). Martek Biosciences Corp....
Items per page:
1 - 10 of 182
BioCentury | Apr 15, 2013
Company News

Martek, Nutraceutical Corp. sales and marketing update

...Neuromins docosahexaenoic acid (DHA) in retail outlets in the U.S. under Nutraceutical's Solaray brand name. Martek Biosciences Corp....
BioCentury | Apr 15, 2013
Company News

Martek management update

Martek Biosciences Corp. (MATK), Columbia, Md. Business: Foods, Drug discovery Hired: Jerome Keller as SVP of sales and marketing, formerly VP of sales at Merck & Co. WIR Staff...
BioCentury | Apr 15, 2013
Company News

Martek sales and marketing update

...acid (DHA) and arachidonic acid (ARA), believed to be associated with mental and visual development. Martek Biosciences Corp....
BioCentury | Apr 15, 2013
Company News

Martek other research news

...milk, and schizophrenia in adults. The company markets Neuromins DHA, a single-nutrient source of DHA. Martek Biosciences Corp....
BioCentury | Apr 15, 2013
Company News

Martek sales and marketing update

...acids docosahexanoic acid (DHA) and arachadonic acid (ARA) that are found in human breast milk. Martek Biosciences Corp....
BioCentury | Apr 15, 2013
Clinical News

Martek regulatory update

...with ARA levels comparable to those found in human breast milk without introducing excess EPA. Martek Biosciences Corp....
BioCentury | Jan 30, 2012
Finance

Small stakes

...2010 for a profit of $2,591. In June 2009, he purchased $5,208 of nutraceuticals play Martek Biosciences Corp....
...which he sold that December for a $2,004 profit. Royal DSM N.V. (Euronext:DSM) acquired Martek...
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

...billion. The four companies were Crucell N.V. , Cypress Bioscience Inc. , Eurand N.V. and Martek Biosciences Corp....
BioCentury | Mar 7, 2011
Company News

Martek, Royal DSM deal

...DSM completed its previously announced offer for Martek (see BioCentury, Jan. 3 & Jan. 24). Martek Biosciences Corp....
BioCentury | Jan 24, 2011
Company News

Martek, Royal DSM deal

...Royal DSM began its cash tender offer to acquire nutraceuticals company Martek for $31.50 per share...
...per share, or about $1.1 billion. The offer expires Feb. 18 (see BioCentury, Jan. 3). Martek Biosciences Corp....
Items per page:
1 - 10 of 182